Divergent Risks of Hematologic Malignancies Associated with GLP-1 Receptor Agonists and SGLT2 Inhibitors: Preliminary Findings from a Pilot Network Meta-Analysis
Authors:
- Pao-Yen LinPLPao-Yen Lin
- Bing-Yan ZengBZBing-Yan Zeng
- Chih-Wei HsuCHChih-Wei Hsu
- Mein-Woei SuenMein-Woei Suen
- Chao-Ming HungCHChao-Ming Hung
- Brendon StubbsBSBrendon Stubbs
- Yen-Wen ChenYCYen-Wen Chen
- Tien-Yu ChenTCTien-Yu Chen
- Wei-Te LeiWLWei-Te Lei
- Jiann-Jy ChenJCJiann-Jy Chen
- Bing-Syuan ZengBZBing-Syuan Zeng
- Kuan-Pin SuKSKuan-Pin Su
Open Access
- 19 November 2025
- journal article
- review article
- Published by MDPI AG in Biomolecules
- Vol. 15 (11) , 1622
Abstract
Background: Although glucagon-like peptide-1 (GLP-1) receptor agonists and sodium–glucose cotransporter 2 (SGLT2) inhibitors have gained attention for their broad therapeutic effects, their influence on hematologic malignancy remains underexplored. Given the high mortality associated with hematologic cancers, clarifying the impact of these agents on such malignancies is essential. Objectives: This pilot network meta-analysis (NMA) aimed to assess the comparative risk of hematologic malignancies—including lymphoma, leukemia, and myeloma—associated with various GLP-1 receptor agonists and SGLT2 inhibitors. Methods: Following Cochrane-recommended confirmatory methods, we systematically searched multiple databases for randomized controlled trials (RCTs) published through 4 December 2024. The primary outcome was the incidence of overall hematologic malignancies. A frequentist random-effects NMA via the netmeta package was conducted, with additional validation through Bayesian NMA for solely sensitivity analyses. Results: Fifty-five RCTs (n = 200,606) were analyzed. Dulaglutide showed a significantly higher risk of overall hematologic malignancy [odds ratio (OR) = 2.18, 95% confidence interval (95%CI) = 1.14–4.19). In contrast, tirzepatide was linked to a significantly reduced risk (OR = 0.14, 95%CI = 0.03–0.60), especially for lymphoma. No statistically significant associations were identified for SGLT2 inhibitors (i.e., 95%CI across 1.0). Conclusions: Our preliminary findings reveal distinct and agent-specific effects of GLP-1 receptor agonists on hematologic malignancy risk. While dulaglutide may elevate the risk, tirzepatide appears protective, particularly against lymphoma. These results call for further long-term mechanistic studies to clarify causality and underlying pathways.Keywords
Funding Information
- NIHR Brendon Stubbs is part funded by the NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust
- Maudsley Charity, King’s College London
This publication has 89 references indexed in Scilit:
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With ObesityJAMA, 2024
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or ObesityJAMA, 2021
- Association between diabetes and haematological malignancies: a population-based studyDiabetologia, 2021
- MetaInsight: An interactive web‐based tool for analyzing, interrogating, and visualizing network meta‐analyses using R‐shiny and netmetaResearch Synthesis Methods, 2019
- Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With SulfonylureaJAMA, 2019
- Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exerciseDiabetologia, 2015
- The Peto odds ratio viewed as a new effect measureStatistics in Medicine, 2014
- HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylureaDiabetologia, 2014
- A basic introduction to fixed-effect and random-effects models for meta-analysisResearch Synthesis Methods, 2010
- Checking consistency in mixed treatment comparison meta‐analysisStatistics in Medicine, 2010